France's UNICANCER Chooses TEMIS and SWORD to Accelerate Clinical Research by Analyzing Patients' Electronic Health Records

Joint project will accelerate the constitution of relevant patient cohorts for clinical research

News provided by

Mar 09, 2015, 09:00 ET

ROCKVILLE, Maryland, March 9, 2015 /PRNewswire/ --

TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, today announced that its solution Luxid® has been chosen by France's UNICANCER, the Federation of French Cancer Centers (CLCCs), as the semantic module for its ConSoRe (Continuum Soin-Recherche) project driven by SWORD Consulting and Services.

Clinical Trials help progress the fight against cancer by validating promising treatments on actual patients. The 20 French CLCCs drive such clinical studies on coherent cohorts of patients who have similar clinical profiles. But identifying patients whose profile matches trial requirements is traditionally a particularly laborious process involving the manual review of potentially millions of patient records. This pre-screening step therefore considerably slows down the launch of clinical studies.

The focus of the ConSoRe project is a search tool enabling Cancer Centers to rapidly aggregate coherent cohorts of patients who meet the required criteria (gender, tumor type, treatment …). "ConSoRe enables researchersto rapidly evaluate the feasibility of their proposed clinical study. If a sufficient number of candidates are identified, they are then contacted to implement the study," explains Emmanuel Reyrat, Information Systems Director at UNICANCER.

ConSoRe implements a data processing workflow that accelerates this identification phase. At the core of this workflow automated by Antidot's AIF and AFS solutions, TEMIS's Luxid® platform extracts medical references, family histories, TNM cancers and tumors classification as well as their locations, from patient records. This information is then indexed as metadata and leveraged in the form of facets to accelerate the search and navigation process within patient records and ultimately the selection of relevant candidates. ConSoRe is currently being tested in 4 pilot CLCCs: Georges-François Leclerc Center in Dijon, Regional Institute of Cancer of Montpellier, Curie Institute in Paris and Léon Bérard Center in Lyon.

"In ConSoRe,patient records are first normalized to a pivot format and then semantically structuredwith the Luxid® platform from TEMIS," said Frederik Joly, Project Manager, SWORD. "We have been working in close collaboration with TEMIS for several years on semantic projects and a genuine relationship of trust has developed between our two companies."

"The digital transformation comes with a 50% annual increase of unstructured content. In healthcare, analytics applied to « Textual Big Data » such as patient records is instrumental both in focusing research, as well as in developingpersonalized, more efficient and inexpensive treatments," said Daniel Mayer, VP Product & Marketing, TEMIS. "ConSoRe further affirms Luxid®'s positioning as a strategic accelerator in healthcare."

About UNICANCER

UNICANCER brings together the 20 French Comprehensive Cancer Centers (FCCC), promotes their cancer research organisation and pools resources and competencies to give a new dynamic to patient care. The French Comprehensive Cancer Centers have held a special place in the French health care system. These private, non-profit establishments are entirely devoted to fighting cancer with a view to public service. They have a threefold mission: patient care, research and teaching. The cancer care and research organisation model of the FCCC has been built around multidisciplinary practice, individualised treatment and a research-healthcare continuum.

UNICANCER in figures: 20 healthcare establishments, more than 110 000 patients hospitalized every year, 18 000 employees, 2 billion euros in total revenue.

Website: http://www.unicancer.fr/en

About TEMIS

TEMIS helps organizations structure, manage and exploit their unstructured information assets. Its flagship platform, Luxid®, identifies and extracts targeted information to semantically enrich content with domain-specific metadata. This enables organizations to intelligently archive, manage, package, deliver, access and analyze their textual Big Data.

TEMIS' innovative solutions have attracted the business of leading scientific organizations such as AAAS (American Association for the Advancement of Science), ASCB, BASF, Bayer Pharma, Elsevier, INRA, Merck KGaA, RSNA, Sanofi, Springer Science+Business Media, Thieme, Thomson Reuters Scientific, the U.S. Department of Agriculture, Volkswagen, Wiley and Wolters Kluwer.

Founded in 2000, TEMIS operates in the United States, Canada, UK, France and Germany, and is represented worldwide through its network of certified partners.

Website: http://www.temis.com Blog:tagline.temis.com Follow us on Twitter: @TEMIS_Group

About SWORD Group

SWORD Group (NYSE Euronext: FR0004180578 SWP) delivers high value business applications (IT Services & Software) to the world's largest companies globally. With operations in 50 countries, SWORD today employs over 1,200 people and generates €117.1m in consolidated revenue.

An international leader in the delivery of Business Process Improvement solutions and data optimization, SWORD's skills, infrastructure and experience help our customers across regulated industries optimize performance, increase efficiencies and maximize return on investment. SWORD has developed expertise in several niche technologies, and in particular in search solutions and semantic data manipulation, through its partnership with TEMIS.

With flexible delivery options, including On Demand and On Premises, combined with our extensive industry expertise, SWORD provides comprehensive support to customers across insurance and healthcare, energy, banking and finance, telecoms, utilities, engineering and construction and the public sector.

Website: http://www.sword-group.com

SOURCE TEMIS